CDC7Cell Division Cycle 7
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
(2006) Importin-[beta] mediates Cdc7 nuclear import by binding to the kinase insert II domain, which can be antagonized by importin-[alpha].
The results showed that the decoction incubation reduced the levels of CCNA1, CCND1, CCND2, CCNH, CDKN1B, MCM2, ORC6L, and WEE1 and increased the levels of CDC7, CDK6, CDK7, E2F3, and RB1 (Table 1).
Moreover, we showed that the cell-cycle arrest was accompanied by down-regulation of CCNA1, CCND1, CCND2, CCNH, CDKN1B, MCM2, ORC6L, and WEE1 and upregulation of CDC7, CDK6, CDK7, E2F3, and RB1.
Thus cells employ Cdc7 to ensure accurate DNA repair during the stage of their lifecycle that is most vulnerable to cancer-causing mutations.
According to Vaziri, the dual role that Cdc7 plays in the cell lifecycle and DNA repair offers a promising target for potential cancer therapies.
Previously, Dr Woolfson was employed as the global clinical lead at Bristol-Myers Squibb, where he was responsible for the development of a portfolio of small-molecule inhibitors including JAK2, CDC7, SMO and IGF-1R/IR.
LBS-007 functions by blocking the kinase activity of CDC7, a key regulator of the cancer cell cycle.
In addition, the company announced it is planning to submit an Investigational New Drug for its Cdc7 inhibitor, SRA141, in the second half of 2018 in order to initiate a Phase 1/2 clinical trial, focused initially on the treatment of colorectal cancer.
The company is also advancing SRA141, a potent, selective, orally bioavailable small molecule inhibitor of Cell division cycle 7 (Cdc7 ) kinase, a key regulator of DNA replication involved in the DDR network, making it a compelling emerging target for the potential treatment of a broad range of tumor types.
- US-based drug development company Lin BioScience has licensed the intellectual property portfolio for a novel inhibitor of CDC7 kinase, the company said.
Under this worldwide exclusive licensing agreement with Columbia University and Memorial Sloan Kettering Cancer Center, Lin BioScience plans to develop this potent CDC7 inhibitor (LBS-007) against a wide range of cancers.
Taverner Consort & Choir & Players / et al.) Funeral I [reissued in 1995AP]; Funeral II (z58c+860) -- Virgin Veritas 5 45159-2 (formerly EMI CDC7 49635-2) with odes z323, 339